Literature DB >> 32358206

Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Camille A Robinson1, J Deanna Wilson2.   

Abstract

In response to the growing impact of the current opioid public health crisis in the United States on adolescents and young adults, pediatricians have an expanding role in identifying opioid use early, preventing escalation of risky use, reducing opioid-related harms, and delivering effective therapies. Research and expert consensus suggest the use of brief interventions focused on reducing risks associated with ongoing opioid use and using motivational interviewing strategies to engage youth in treatment. Because fatal opioid overdose remains a major cause of opioid-related mortality among youth, delivering overdose education as part of any visit in which a youth endorses opioid use is one evidence-based strategy to decrease the burden of opioid-related mortality. For youth that are injecting opioids, safe injection practices and linkage to needle or syringe exchanges should be considered to reduce complications from injection drug use. It is crucial that youth be offered treatment at the time of diagnosis of an opioid use disorder (OUD), including medications, behavioral interventions, and/or referral to mutual support groups. The 2 medications commonly used for office-based OUD treatment in adolescents are extended-release naltrexone (opioid antagonist) and buprenorphine (partial opioid agonist), although there is a significant treatment gap in prescribing these medications to youth, especially adolescents <18 years of age. Addiction is a pediatric disease that pediatricians and adolescent medicine physicians are uniquely poised to manage, given their expertise in longitudinal, preventive, and family- and patient-centered care. Growing evidence supports the need for integration of OUD treatment into primary care.
Copyright © 2020 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32358206      PMCID: PMC7880138          DOI: 10.1542/peds.2019-2056C

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  83 in total

1.  Association of Opioid Prescriptions From Dental Clinicians for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse.

Authors:  Alan R Schroeder; Melody Dehghan; Thomas B Newman; Jason P Bentley; K T Park
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

Review 2.  Family-based therapies for adolescent alcohol and drug use: research contributions and future research needs.

Authors:  Howard A Liddle
Journal:  Addiction       Date:  2004-11       Impact factor: 6.526

Review 3.  Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.

Authors:  Brandon D L Marshall; Traci C Green; Jesse L Yedinak; Scott E Hadland
Journal:  Int J Drug Policy       Date:  2016-02-04

4.  Family-based treatment for adolescent substance abuse: controlled trials and new horizons in services research.

Authors:  Aaron Hogue; Howard A Liddle
Journal:  J Fam Ther       Date:  2009-05-01

Review 5.  Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.

Authors:  P Todd Korthuis; Dennis McCarty; Melissa Weimer; Christina Bougatsos; Ian Blazina; Bernadette Zakher; Sara Grusing; Beth Devine; Roger Chou
Journal:  Ann Intern Med       Date:  2016-12-06       Impact factor: 25.391

6.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

7.  Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

Authors:  Colleen T LaBelle; Steve Choongheon Han; Alexis Bergeron; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2015-06-26

8.  Access to substance use treatment among young adults who use prescription opioids non-medically.

Authors:  Elliott J Liebling; Jesse L Yedinak; Traci C Green; Scott E Hadland; Melissa A Clark; Brandon D L Marshall
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-11-29

Review 9.  Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.

Authors:  Ricardo M Fernandes; Maria Cary; Gonçalo Duarte; Gonçalo Jesus; Joana Alarcão; Carla Torre; Suzete Costa; João Costa; António Vaz Carneiro
Journal:  BMC Public Health       Date:  2017-04-11       Impact factor: 3.295

10.  Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders.

Authors:  Miriam Komaromy; Dan Duhigg; Adam Metcalf; Cristina Carlson; Summers Kalishman; Leslie Hayes; Tom Burke; Karla Thornton; Sanjeev Arora
Journal:  Subst Abus       Date:  2016       Impact factor: 3.716

View more
  3 in total

1.  Mental Health Conditions and Substance Use Disorders Among Youth Subsequently Diagnosed With Opioid Use Disorder or Opioid Poisoning.

Authors:  Edeanya Agbese; Bradley D Stein; Benjamin G Druss; Andrew W Dick; Rosalie L Pacula; Douglas L Leslie
Journal:  J Addict Med       Date:  2022 May-Jun 01       Impact factor: 4.647

2.  An Urgent Need to Focus on Youth With Opioid Use Disorder.

Authors:  J Deanna Wilson; Sarah M Bagley
Journal:  J Adolesc Health       Date:  2022-08       Impact factor: 7.830

Review 3.  Addressing adolescent substance use with a public health prevention framework: the case for harm reduction.

Authors:  James Michael Winer; Amy M Yule; Scott E Hadland; Sarah M Bagley
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.